This editorial focuses on the current state of science and public health in the U.S. during the 2020 presidential election season.

This commentary provides an overview of four randomized clinical trials on the use of geriatric assessment to guide decisions and interventions for cancer care. These studies show the effect of geriatric interventions on oncological outcomes, including toxicity, quality of life, and survival.

This commentary discusses evidence supporting the importance of full palliative care dose intensity in outcomes for patients with cancer.

This commentary outlines the strategy employed by a multidisciplinary immune-related toxicity team to evaluate patients who may be at high risk for the development of immune-related toxicity, in particular, those with preexisting lung conditions and subsequent immune-related pneumonitis.

This article provides a promising report of tepotinib efficacy in a patient with non-small cell lung cancer harboring an HLA-DRB1-MET gene fusion.

This article presents a case-based discussion and review of the literature pertaining to immune-mediated diabetes associated with immune checkpoint blockade.

Case reports for two patients with NRAS-mutant metastatic melanoma are presented, highlighting toxicities associated with binimetinib, as well as the efficacy of an intermittent dosing schedule and possible mechanisms preventing resistance in targeted therapy.

This study investigated whether changes in ¹⁸F-FES positron emission tomography uptake could be used for the early prediction of treatment response in patients with metastatic breast cancer who received a fulvestrant 500 mg regimen.

Everolimus has been incorporated into clinical practice, and its use is supported by current treatment guidelines; however, the literature on patterns of everolimus use and associated adverse events is limited. This article describes patterns of everolimus use in a large cohort of patients with metastatic breast cancer and the rates of hospitalizations and emergency room visits that patients experienced while receiving this therapy.

This article reports the current landscape of biomarkers in breast cancer, focusing on patients using comprehensive genomic profiling and PD-L1 immunohistochemistry in addition to the previous standard of care diagnostics for hormone receptor and human epidermal receptor 2 identification. The relationship between different immunotherapy biomarkers in patients with triple-negative breast cancer is examined.

The emergence of precision medicine has identified genomic variants, such as NTRK gene fusion, microsatellite instability (MSI), HER2 amplification, and POLE pathogenic mutation, as potential agonistic biomarkers for immune or targeted therapies. This article examines NTRK, HER2, and POLE in a cohort of Chinese patients with colorectal cancer.

This article presents the results of a phase I study evaluating the safety and efficacy of andecaliximab in advanced pancreatic adenocarcinoma.

Most studies that support the benefit of perioperative therapy for resectable pancreatic ductal adenocarcinoma (PDAC) are based on younger patients. This study evaluated the role of surgery, neoadjuvant therapy, and adjuvant therapy in older patients with anatomically resectable PDAC to test the hypothesis that older patients with resectable PDAC who received surgery, neoadjuvant therapy, or adjuvant therapy could have improved survival outcomes compared with those who did not receive such treatments.

New treatment approaches are needed for esophagogastric cancer. c-MET gene-amplified tumors are a potential new target. This article compares patients with and without MET-amplified esophagogastric cancer to identify possible treatment approaches.

This article provides a descriptive overview of the feasibility and efficacy results of therapeutic de-escalation of FOLFIRINOX in patients with metastatic pancreatic cancer.

Focusing on urothelial malignancies, this review summarizes the oncogenic signaling of FGFR alterations, clinical trials of FGFR inhibitors, and resistance patterns.

This case report describes the first known case of a patient with ovarian cancer with ROS1 rearrangement who experienced radiographic partial response after treatment with crizotinib.

This cooperative study analyzed the clinical, laboratory, and pathologic variables of patients with idiopathic multicentric Castleman disease (iMCD), resulting in a proposal for an iMCD international prognostic index that can help physicians agree on a treatment algorithm for iMCD.

This study evaluated patients treated with ibrutinib for chronic lymphocytic leukemia and whether disease flares occur in the setting of temporary interruption of ibrutinib therapy.

This phase II clinical study evaluated the efficacy and toxicity of concurrent chemoradiotherapy using single-drug pegaspargase for patients with nasal-type extranodal NK/T-cell lymphoma.

This article evaluates the effect of routine baseline blood parameters on outcomes of patients with advanced cancers treated in phase I trials testing immunotherapy agents as monotherapy or in combination.

Immune checkpoint inhibitors have recently been investigated in small cell lung cancer. This review provides guidance on the use of these agents in extensive-stage small cell lung cancer based on phase III evidence.

Improved diagnostic and treatment approaches are needed for patients with non-small cell lung cancer. This article evaluates the testing patterns and outcomes associated with overall companion diagnostic testing in real-world clinical practice.

Evidence shows improved survival for patients with advanced melanoma treated with the CTLA-4 inhibitor, ipilimumab, and PD-1 inhibitors. This article examines characteristics and outcomes of patients with advanced melanoma and organ dysfunction treated with immune checkpoint inhibitors, for patients with both baseline dysfunction and treatment-emergent toxicity, using a dataset of real world patients.

This article reviews diagnostic tools and applied treatments for leptomeningeal spread, a severe complication of glioblastoma raising diagnostic and therapeutic challenges in clinical routine. The importance of molecular testing and its importance in the setting of molecular targeted therapies is also reviewed.

This article reports on the activity of cytotoxic chemotherapy in patients with inflammatory myofibroblastic tumors, focusing on anthracycline-based regimens, the front-line standard treatment in sarcomas, and methotrexate and/or vinorelbine or vinblastine. Data available on other cytotoxic regimens are also reported.

Skin rash is a common imatinib-associated adverse event and may affect compliance. This phase II study was conducted to evaluate whether imatinib-associated severe skin rash can be managed with systemic steroids without dose reduction or interruption of imatinib.

The feasibility and efficacy of mindfulness-based interventions for patients with advanced cancer have not been widely examined. This article describes a couple-based Meditation intervention compared with a supportive expressive intervention and a usual care control group, targeting psychospiritual distress in patients with metastatic lung cancer and their spousal caregivers.

Few studies have focused on patient attrition in the context of personalized oncology studies. This article examines factors contributing to the loss of patients enrolled in a precision medicine trials.

Regulatory approval of immune checkpoint inhibitors (ICI) is restricted to anatomically defined cancers with a known primary. This article reports cases submitted for 92-gene assay testing with an unknown or uncertain diagnosis for which the subsequent post-test report included a tumor type linked to an FDA-approved ICI therapy, with the goal of identifying characteristics of cancers of unknown primary tumors that might benefit from immunotherapy.

Considering the increase in industry-sponsored cancer clinical trials, the use of professional medical writers for publication of trial results has become an increasingly important topic. This brief communication reports the current rate of involvement of medical writers in publications of cancer clinical trials.

This narrative describes an interaction between an oncologist and a patient who had experienced such deterioration, in the intervening period since last visit, that she was unrecognizable. The author reflects on the enormity of patients’ lives outside of their brief clinic visits.

The search for research funding is challenging. This narrative describes how passions for research and bicycling led to a successful fundraising event.

This letter to the editor proposes techniques for use in telemedicine, especially as related to delivering difficult news by video.

This letter to the editor responds to recent advice related to delivering difficult news via telemedicine, further encouraging productive discussions on this challenging topic.

This letter to the editor responds to remarks on the authors' recently published article on the role of HER2 as a negative prognostic factor in completely resected biliary tract cancer.